CSL Limited (CMXHF)
OTCMKTS
· Delayed Price · Currency is USD
172.36
+12.41 (7.76%)
Feb 20, 2025, 3:00 PM EST
CSL Limited Revenue
CSL Limited had revenue of $8.48B in the half year ending December 31, 2024, with 18.08% growth. This brings the company's revenue in the last twelve months to $15.23B, up 7.41% year-over-year. In the fiscal year ending June 30, 2024, CSL Limited had annual revenue of $14.80B with 11.19% growth.
Revenue (ttm)
15.23B
Revenue Growth
+7.41%
P/S Ratio
n/a
Revenue / Employee
465.78K
Employees
32,698
Market Cap
80.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 14.80B | 1.49B | 11.19% |
| Jun 30, 2023 | 13.31B | 2.75B | 26.02% |
| Jun 30, 2022 | 10.56B | 252.00M | 2.44% |
| Jun 30, 2021 | 10.31B | 1.16B | 12.67% |
| Jun 30, 2020 | 9.15B | 612.20M | 7.17% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.79B |
| SS Innovations International | 16.04M |
| Veradigm | 1.53B |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 188.29M |
| Northwest Biotherapeutics | 1.60M |
| BioStem Technologies | 210.49M |
| SANUWAVE Health | 29.30M |
CSL Limited News
- 3 days ago - CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 9 days ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - PRNewsWire
- 11 days ago - European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) - PRNewsWire
- 12 days ago - Half Year 2025 CSL Ltd Earnings Presentation Transcript - GuruFocus
- 12 days ago - CSL Limited 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 12 days ago - CSL Limited (CSLLY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years - Benzinga
- 16 days ago - CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B - PRNewsWire